I apologize, but I thought the intent behind our committee discussion today was about drug shortages. The conversation you seem to be having, albeit we haven't made it to a question, is all about drug pricing. I wanted to make sure that we were staying on point.
This is a very important issue to me—drug shortages, that is—as is drug pricing, but they are separate—